vTv Therapeutics (VTVT) Competitors $14.59 -0.36 (-2.41%) Closing price 08/1/2025 03:42 PM EasternExtended Trading$14.57 -0.02 (-0.14%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTVT vs. EPRX, TVGN, CTMX, ENGN, KYTX, IPHA, SXTC, GALT, ACRS, and LYELShould you be buying vTv Therapeutics stock or one of its competitors? The main competitors of vTv Therapeutics include Eupraxia Pharmaceuticals (EPRX), Semper Paratus Acquisition (TVGN), CytomX Therapeutics (CTMX), enGene (ENGN), Kyverna Therapeutics (KYTX), Innate Pharma (IPHA), China SXT Pharmaceuticals (SXTC), Galectin Therapeutics (GALT), Aclaris Therapeutics (ACRS), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry. vTv Therapeutics vs. Its Competitors Eupraxia Pharmaceuticals Semper Paratus Acquisition CytomX Therapeutics enGene Kyverna Therapeutics Innate Pharma China SXT Pharmaceuticals Galectin Therapeutics Aclaris Therapeutics Lyell Immunopharma Eupraxia Pharmaceuticals (NASDAQ:EPRX) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment. Do institutionals & insiders have more ownership in EPRX or VTVT? 17.5% of vTv Therapeutics shares are owned by institutional investors. 4.2% of vTv Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is EPRX or VTVT more profitable? vTv Therapeutics' return on equity of -121.46% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eupraxia PharmaceuticalsN/A -367.73% -112.23% vTv Therapeutics N/A -121.46%-46.75% Do analysts recommend EPRX or VTVT? Eupraxia Pharmaceuticals currently has a consensus price target of $11.00, indicating a potential upside of 107.39%. vTv Therapeutics has a consensus price target of $35.50, indicating a potential upside of 143.32%. Given vTv Therapeutics' higher possible upside, analysts plainly believe vTv Therapeutics is more favorable than Eupraxia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17vTv Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings & valuation, EPRX or VTVT? vTv Therapeutics has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than vTv Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEupraxia PharmaceuticalsN/AN/A-$25.50M-$0.76-6.98vTv Therapeutics$1.02M45.63-$18.46M-$3.01-4.85 Does the media prefer EPRX or VTVT? In the previous week, Eupraxia Pharmaceuticals had 7 more articles in the media than vTv Therapeutics. MarketBeat recorded 8 mentions for Eupraxia Pharmaceuticals and 1 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.67 beat Eupraxia Pharmaceuticals' score of 0.61 indicating that vTv Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive vTv Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, EPRX or VTVT? Eupraxia Pharmaceuticals has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. SummaryvTv Therapeutics beats Eupraxia Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get vTv Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTVT vs. The Competition Export to ExcelMetricvTv TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.76M$3.00B$5.47B$9.53BDividend YieldN/A2.43%4.74%4.08%P/E Ratio-4.8517.6228.6723.80Price / Sales45.63268.97422.2688.08Price / CashN/A41.9535.4557.96Price / Book3.268.508.275.55Net Income-$18.46M-$55.06M$3.24B$259.03M7 Day Performance-5.44%-3.98%-3.63%-4.56%1 Month Performance-3.12%9.59%4.40%4.49%1 Year Performance-1.25%6.72%25.97%18.05% vTv Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTVTvTv Therapeutics2.1409 of 5 stars$14.59-2.4%$35.50+143.3%-0.3%$47.76M$1.02M-4.859Upcoming EarningsGap DownEPRXEupraxia Pharmaceuticals2.5434 of 5 stars$5.64+2.7%$11.00+95.2%+85.5%$197.40MN/A-7.4229Upcoming EarningsHigh Trading VolumeTVGNSemper Paratus Acquisition2.9693 of 5 stars$1.08+1.9%$10.00+825.9%+61.5%$194.93MN/A0.003News CoverageUpcoming EarningsShort Interest ↑CTMXCytomX Therapeutics3.9953 of 5 stars$2.39-0.4%$5.33+123.2%+75.4%$193.49M$138.10M4.98170News CoverageUpcoming EarningsAnalyst ForecastENGNenGene3.4559 of 5 stars$3.64-1.6%$23.29+539.7%-56.5%$189.09MN/A-2.2131KYTXKyverna Therapeutics2.8584 of 5 stars$4.33flat$18.50+327.3%-56.2%$187.14MN/A-1.2896Positive NewsIPHAInnate Pharma2.3444 of 5 stars$2.20+8.4%$11.00+400.0%-1.4%$187.13M$21.77M0.00220Gap DownHigh Trading VolumeSXTCChina SXT Pharmaceuticals0.4878 of 5 stars$1.56-1.9%N/A-80.3%$184.48M$1.93M0.0090Analyst UpgradeGALTGalectin Therapeutics2.5126 of 5 stars$3.06+5.2%$6.00+96.1%+63.3%$184.18MN/A-4.259Positive NewsACRSAclaris Therapeutics2.0056 of 5 stars$1.68-1.2%$8.71+418.7%+15.9%$184.08M$18.72M-1.21100News CoveragePositive NewsUpcoming EarningsAnalyst RevisionLYELLyell Immunopharma2.9933 of 5 stars$13.73+10.5%$15.00+9.2%-63.3%$183.92M$60K-0.55270Upcoming EarningsGap DownHigh Trading Volume Related Companies and Tools Related Companies EPRX Alternatives TVGN Alternatives CTMX Alternatives ENGN Alternatives KYTX Alternatives IPHA Alternatives SXTC Alternatives GALT Alternatives ACRS Alternatives LYEL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTVT) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding vTv Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share vTv Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
